FLEMINGTON, N.J.--(BUSINESS WIRE)--Sept. 21, 2006--NovaDel Pharma Inc. (AMEX: NVD) today announced that its Board of Directors has appointed Steven B. Ratoff as Chairman of the Board of Directors, effective as of the Company's Board of Directors meeting on September, 15, 2006. Mr. Ratoff has served on the Board of Directors of the Company since his election to the Board of Directors on January 17, 2006. Mr. Ratoff is currently the Chairman of the Board of Axonyx, Inc. a development stage CNS-focused biopharmaceutical company that has entered into a merger agreement with TorreyPines Therapeutics, Inc. Mr. Ratoff is also a venture partner with ProQuest Investments, a health care venture capital firm. Dr. Jan Egberts, President and Chief Executive Officer of Novadel, will no longer serve as Chairman, but will remain a member of the Board of Directors.
